When I was working with endocrinologists they would often place their type one patients on metformin. I would share this with primary prescribers, and they too had good results using a type 2 drug for insulin dependent patients. We now have more choices than ever for patients and it only …

Meta-analysis explores safety and efficacy of sodium-glucose co-transporter 2 inhibitors in patients with type 1 diabetes.

Females with breast cancer and diabetes have poorer prognosis than those with breast cancer without diabetes, but why?

Although the risk of end-stage renal disease remains high for individuals with type 1 diabetes, lifetime likelihood of ESRD has substantially decreased over the last 50 years.

Study in England links high HbA1c levels to long-term cognitive decline.

Insulin resistance has been proposed as one of the causes of poor glycemic control in youth with type 1 diabetes who have excess weight or obesity.

The suggested hierarchy of usage (AACE Algorithm) for a patient on metformin who has not reached goal according to the new 2018 AACE goal in 3 months is: A. GLP-1RA, SGLT-2i, TZD, Basal Insulin, DPP4i B. SGLT-2i, GLP-1RA, TZD. DPP4i, Basal Insulin C. GLP-IRA, DPP4i, GLP-1RA, Bromocriptine QR D. SGLT-2i, TZD, GLP-1RA, Colesevelem E. SGLT-21, GLP-1RA, Basal Insulin, Colesevelem Follow the link for the answer.

Do you prescribe sleep for your patients? Follow the link to see how you and your colleagues compare.

There seems to be a consensus amongst medical professionals and researchers that patients don’t want to test their glucose regardless of how bad their condition is. It appears that CGMS is the future according to a lot of experts. But is it feasible in the real world? This week, we …

In part 7, the conclusion of this Exclusive Interview, Dr. Ray Kausik talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 convention in San Diego, CA about the side effects so far of the new inhibitor drug and watching for reactions.